Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FISH Testing Guides Treatment of CLL: New Drugs on Horizon

January 12th 2012

FISH testing for genetic abnormalities is the key to appropriate treatment selection for patients with CLL.

Using Molecular Markers in AML for Prediction, Treatment, and Monitoring

January 5th 2012

Several molecular markers for AML are now used at top-tier cancer centers for prediction, treatment selection, and monitoring response.

New Assays Open Window in Evaluating Leukemia Types

January 5th 2012

Genetic markers are becoming a more integral part of diagnosing cancer and determining which patients will encounter more aggressive forms of their disease.

Dr. Zelenetz Discusses the Winter Hematology Meeting

January 5th 2012

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses the Winter Hematology Meeting

Dr. Lukina Discusses Timely Gaucher Disease Diagnosis

December 24th 2011

Dr. Elena Lukina Discusses Timely Gaucher Disease Diagnosis

Dr. Sehn Discusses the GAUSS Obinutuzumab Trial

December 22nd 2011

Dr. Laurie Sehn, from the British Columbia Cancer Agency, Discusses the GAUSS Obinutuzumab Trial

Dr. Zelenetz Discusses Brentuximab Vedotin

December 22nd 2011

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, Discusses Brentuximab Vedotin

Dr. Couriel Discusses Treating GVHD With Photopheresis

December 20th 2011

Dr. Daniel Couriel, from the Unversity of Michigan Comprehensive Cancer Center, Discusses Treating GVHD With Photopheresis

Update on Bone Disease in Multiple Myeloma

December 19th 2011

Bone disease occurs in about 84% of patients with multiple myeloma and is responsible for a great deal of morbidity, including pain, hypercalcemia, compromised quality of life, and pathological fracture.

Dr. Feldman Discusses Using Doxil for CTCL

December 19th 2011

Dr. Tatyana Feldman, from the John Theurer Cancer Center, Discusses Using Doxil for CTCL

What is the best way to administer bendamustine, since some clinicians classify it as an irritant and others classify it as a vesicant?

December 16th 2011

Because of bendamustine's potential to cause pain and erythema to the extent that hospitalization has been required for some patients, it would be prudent to administer bendamustine using vesicant precautions.

Day in the Life of an Oncology/Hematology Fellowship Program Director

December 15th 2011

Trainees have sat in this hot seat at the front of the room for decades. It's not really warm, of course. This is where the fellow sits who is asked to review the findings, come up with a differential diagnosis, and devise a plan for the case in question.

What Oncology and Hematology Fellows Can Do to Reduce Their Loan Debt

December 15th 2011

While debt from medical school loans is inevitable for most oncology and hematology fellows, there are strategies they can consider to lessen that burden.

Dr. Mato on the Benefits of the JTCC Retrospective Trial

December 13th 2011

Dr. Anthony Mato From the John Theurer Cancer Center Discusses the Benefits of the JTCC Retrospective Trial

Final Analysis of VISTA Upholds Survival Benefit of Bortezomib at 5 Years: No Increase in Secondary Malignancies Found

December 13th 2011

The phase III VISTA trial upholds a persistent and statistically significant survival benefit for bortezomib in previously untreated multiple myeloma patients.

Novel CD20 Monoclonal Antibody Achieves Higher Response Rates Than Rituximab in Relapsed Non-Hodgkin Lymphoma

December 12th 2011

Treatment with GA101 (obinutuzumab) in patients with relapsed non-Hodgkin lymphoma (NHL) resulted in higher response rates compared with rituximab.

Dr. Anasetti Discusses the Trade-offs of BMT and PBSC

December 12th 2011

Dr. Claudio Anasetti from the H. Lee Moffitt Cancer Center Discusses the Trade-offs of BMT and PBSC

Novel Agent Targeting the B-Cell Receptor Shows Efficacy, Without Myelosuppression, in Chronic Lymphocytic Leukemia

December 12th 2011

First drug targeting Bruton's tyrosine kinase (Btk) produced high rates of remission in patients with CLL.

Chemotherapy Alone Increases Overall Survival for Early-stage Hodgkin Lymphoma

December 12th 2011

Twelve-year results from a Canadian Cancer Society Research Institute study shows chemotherapy alone increases survival in patients with Hodgkin Lymphoma.

Dr. Sehn Discusses the Efficacy of the CD20 Agent GA101

December 11th 2011

Dr. Laurie Sehn from the British Columbia Cancer Agency Discusses the Efficacy of the CD20 Agent GA101